Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Outlook Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$56.15M. For fiscal 2025 it was -$51.83M. The highest annual figure on record is -$15.51M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$51.83M | – |
| FY2024 | Sep 30, 2024 | -$68.79M | – |
| FY2023 | Sep 30, 2023 | -$42.97M | – |
| FY2022 | Sep 30, 2022 | -$56.67M | – |
| FY2021 | Sep 30, 2021 | -$54.25M | – |
| FY2020 | Sep 30, 2020 | -$31.79M | – |
| FY2019 | Sep 30, 2019 | -$32.29M | – |
| FY2018 | Sep 30, 2018 | -$33.04M | – |
| FY2017 | Sep 30, 2017 | -$15.51M | – |
| FY2016 | Sep 30, 2016 | -$45.48M | – |
| FY2015 | Sep 30, 2015 | -$27.48M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$21.01M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$7.83M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$14.94M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$12.38M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$11.90M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$16.58M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$10.97M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$16.98M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$19.51M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$19.27M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$13.03M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$12.74M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$13.22M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$8.11M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$8.90M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$10.25M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$10.99M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$8.99M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$13.32M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$12.08M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$5.96M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$7.08M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$6.67M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$5.94M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$10.31M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$6.26M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$9.78M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$8.39M | -10611.9% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$8.54M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$7.44M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$8.67M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $79.85K | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$5.63M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$4.11M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$5.84M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$10.37M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$16.04M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$7.06M | – |
See a number that looks wrong?